Tests a bergamot and artichoke supplement for high cholesterol in adults
Tests a bergamot and artichoke supplement in adults with high cholesterol.
Plain-language title generated from the registry record
Registry title: Study To Evaluate The Efficacy And Safety Of A Nutritional Supplement Based On Bergamot, Artichoke And Other Ingredients For Reducing Cholesterol Levels In Patients With Hypercholesterolemia (Metachol+)
Key facts
- Where
- Cartagena, Madrid, and Mazarrón, SpainSee the 6 sites
Where in Spain
- Centro de Salud Casco AntiguoCartagena, SpainTaking people
- Centro de Salud Isaac PeralCartagena, SpainTaking people
- Centro de Salud Avenida de AragónMadrid, SpainNot yet recruiting
- Centro de Salud DarocaMadrid, SpainTaking people
- Centro de Salud GoyaMadrid, SpainNot yet recruiting
- Centro de Salud de MazarrónMazarrón, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Laboratoires Arkopharma
- Trial code
- NCT07178769
- Record updated
- 17 September 2025
- Original description
The goal of this clinical trial with food supplement is to evaluate the effectiveness of a nutritional supplement based on bergamot, artichoke and other ingredients through low-density lipoprotein (LDL) values after four months of treatment compared to maintaining healthy lifestyle habits.Read full original descriptionShow less
Multicenter Randomized Open-label Controlled Clinical Study to Evaluate the Efficacy and Safety of a Nutritional Supplement Based on Bergamot, Artichoke and Other Ingredients After Four Months of Treatment in Reducing Cholesterol Levels in Patients With Moderate or Mild Hypercholesterolemia
The goal of this clinical trial with food supplement is to evaluate the effectiveness of a nutritional supplement based on bergamot, artichoke and other ingredients through low-density lipoprotein (LDL) values after four months of treatment compared to maintaining healthy lifestyle habits.
The secondary objectives are
* Evaluate the improvement of the lipid profile compared to maintaining healthy lifestyle habits. * Evaluate the difference in effect between 1 tablet and 2 tablets daily in improving the lipid profile. * Evaluate changes in anthropometric data and vital signs. * Evaluate adherence to treatment * Evaluate the safety profile of the product * Evaluate satisfaction with treatment
There are three treatment arms:
1. Arm 1 (Gr 1): Patients being treated with a nutritional supplement based on bergamot, artichoke and other ingredients with one capsule every night at dinner with a glass of water for four months. 2. Arm 2 (Gr 2): Patients treated with a nutritional supplement based on bergamot, artichoke and other ingredients with two capsules every night at dinner with a glass of water for four months. 3. Arm 3 (Control): Patients not taking METACHOL+. All patients in the study will be recommended to lead an active life and a healthy diet, providing them with instructions to follow according to their usual clinical practice.
It is expected to recruit 207 patients in total, 69 in each group/arm
Inclusion: Patients who are willing and able to understand and sign the informed consent after the nature of the study has been fully explained to them and they have passed the inclusion/exclusion criteria; Patients aged greater than or equal to 18 years; Patients with moderate or mild cardiovascular risk, who have LDL levels greater than 130 mg/dl.
Exclusion: Use of any other drug or food supplement for the treatment of hypercholesterolemia during the 30 days prior to selection; Allergy or hypersensitivity to any of the components of the study treatment; Decompensated cardiovascular disease, decompensated diabetes mellitus, decompensated HTN; Serious medical conditions such as: cancer, serious chronic illness considered incompatible with participation in the study or others that may interfere with the study; HIV-AIDS, Pregnancy or breastfeeding, occlusion of the central retinal artery (of foreseeable vascular origin), history of cardiovascular disease and familial hypercholesterolemia; Liver, kidney or muscle disorders; Psychiatric disorders or inability to sign the consent; Subjects with extreme eating habits and/or with a significant history of anorexia nervosa, bulimia and other eating disorders.